Some Asians Taking Certain Epilepsy Medications Might Experience Adverse Skin Reactions, FDA Says

Main Category: Epilepsy
Also Included In: Dermatology;  Regulatory Affairs / Drug Approvals
Article Date: 26 Nov 2008 - 12:00 PST

email to a friend   printer friendly   view / write opinions   rate article

FDA is investigating whether certain medications used to control epileptic seizures can cause severe skin blisters and bleeding for some Asian patients, the AP/Detroit Free Press reports. FDA recommended that doctors closely monitor Asian patients taking epilepsy drugs such as Dilantin, Phenytek and Cerebyx.

Last year, the agency recommended that Asian patients taking the epilepsy drug carbamazepine, sold under brand names such as Tegretol and Carbatrol, be screened because of similar skin reactions. In most cases, patients develop a reaction within the first few months of starting the medications.

According to preliminary data, patients who carry a gene known as HLA-B1502 appear to have an increased risk of developing the serious skin reactions and about 10% to 15% of such patients are of Asian descent, specifically from parts of China, Indonesia, Malaysia, the Philippines and Thailand. About 2% to 4% of South Asians, including Indians, also carry the gene, according to the AP/Free Press. According to FDA, there is not yet enough information to recommend that the patients be screened for the gene (AP/Detroit Free Press, 11/24).

An FDA alert on the issue is available online.

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation.

© 2008 Advisory Board Company and Kaiser Family Foundation. All rights reserved.